Zeinab Ahmed Ashour
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Zeinab Ahmed Ashour has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Ashraf Okba
Internal Medicine, Allergy and Clinical Immunology Department, Faculty of Medicine - Ain Shams University, Cairo, Egypt
1 shared publication - Fawzia Abo Ali
Internal Medicine, Allergy and Clinical Immunology Department, Faculty of Medicine - Ain Shams University, Cairo, Egypt
1 shared publication - Nermine A. Elnour Melek
Internal Medicine, Allergy and Clinical Immunology Department, Faculty of Medicine - Ain Shams University, Cairo, Egypt
1 shared publication - Reham Mohamed El Shabrawy
Microbiology and Immunology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt.
1 shared publication - Salwa Seddik Hosny
Internal Medicine and Endocrinology, Faculty of Medicine, Ain Shams University, Cairo, Egypt
1 shared publication
Latest Publications
- Open Access
- 27 November 2025
- Published by Springer Nature in Clinical and Experimental Medicine
- Vol. 26 (1)
The frequency of regulatory T-cells in Hashimoto’s thyroiditis and Graves’ disease
Till now, the management of autoimmune thyroid diseases (AITD) depends on symptomatic treatment and replacement or anti-thyroid therapy. Uncovering the pathophysiologic mechanisms of autoimmunity provides hope for new insights into management. These new treatments aim to modulate the immune reaction and stop the autoimmune process. T regulatory cells (Tregs) are central in antagonising autoimmunity. This study aimed to compare the number of CD4/CD25/FOXP3 T regulatory cells in the different forms of autoimmune thyroid diseases and in the normal population, and to compare the number of CD4 + CD25 + FOXP3 + T regulatory cells between the different forms of AITD, HT, and GD. Also, to investigate the difference in the number of CD4/CD25/FOXP3 T regulatory cells in AITD associated with allergic disorders on one hand and autoimmune thyroid diseases not associated with allergic disorders on the other hand. This study included 18 patients suffering from Hashimoto’s thyroiditis (HT), 15 patients suffering from Graves’ disease (GD); and, for comparison, the Tregs level was measured in 15 healthy control patients. A statistically significant decrease was found regarding CD4/CD25, CD25/FOXP3 percentages and CD4/CD25/FOXP3 absolute number between patients of AITD and the normal population. The absolute number of CD4/CD25/FOXP3 was lower in the GD group than in HT group. Allergic comorbidities do not influence Tregs percentage or their CD4/CD25/FOXP3 absolute number in any of the AITD forms. Tregs may be a potential therapeutic target for AITD.
- 27 November 2025
- Published by Springer Nature in Clinical and Experimental Medicine
- Vol. 26 (1)
Open AccessThe frequency of regulatory T-cells in Hashimoto’s thyroiditis and Graves’ disease
Till now, the management of autoimmune thyroid diseases (AITD) depends on symptomatic treatment and replacement or anti-thyroid therapy. Uncovering the pathophysiologic mechanisms of autoimmunity provides hope for new insights into management. These new treatments aim to modulate the immune reaction and stop the autoimmune process. T regulatory cells (Tregs) are central in antagonising autoimmunity. This study aimed to compare the number of CD4/CD25/FOXP3 T regulatory cells in the different forms of autoimmune thyroid diseases and in the normal population, and to compare the number of CD4 + CD25 + FOXP3 + T regulatory cells between the different forms of AITD, HT, and GD. Also, to investigate the difference in the number of CD4/CD25/FOXP3 T regulatory cells in AITD associated with allergic disorders on one hand and autoimmune thyroid diseases not associated with allergic disorders on the other hand. This study included 18 patients suffering from Hashimoto’s thyroiditis (HT), 15 patients suffering from Graves’ disease (GD); and, for comparison, the Tregs level was measured in 15 healthy control patients. A statistically significant decrease was found regarding CD4/CD25, CD25/FOXP3 percentages and CD4/CD25/FOXP3 absolute number between patients of AITD and the normal population. The absolute number of CD4/CD25/FOXP3 was lower in the GD group than in HT group. Allergic comorbidities do not influence Tregs percentage or their CD4/CD25/FOXP3 absolute number in any of the AITD forms. Tregs may be a potential therapeutic target for AITD.